H epatitis E virus (HEV) is a common cause of acute hepatitis in developing countries where HEV Genotypes 1 and 2 cause large outbreaks via fecal-oral (water-or food-borne) spread. 1 In North America, HEV had been presumed to be primarily a travel-related disease. 2, 3 In recent years, HEV is increasingly recognized as a zoonotic pathogen in Europe and North America, 4 primarily involving Genotype 3 and, to a lesser extent, Genotype 4, identified in swine and other livestock. 5 HEV infection in humans usually results in asymptomatic infection but severe cases have been reported and infection of immunocompromised hosts can lead to chronic disease that can evolve to severe liver injury. 4 Human HEV infection has been linked to consumption of raw and undercooked pork products 6 as well as game and possibly shellfish 5, 7, 8 Contact with live animals 7 may also play a role.
ABBREVIATIONS: CBS 5 Canadian Blood Services; H-Q 5
H ema-Qu ebec. Transfusion transmission of hepatitis E is well described, [9] [10] [11] [12] mostly due to Genotype 3, but the number of cases reported in the literature is small, even in HEVendemic countries, possibly because the viremic period is short, infection may be asymptomatic or underrecognized, and many recipients may be immune from prior HEV infection. In nonendemic countries, symptomatic blood product recipients are unlikely to be tested for HEV due to a lack of awareness of the potential for transfusion transmission of this virus. Recent seroprevalence studies of blood donor populations 11, [13] [14] [15] [16] [17] have shown that the risk of HEV transfusion transmission may be higher than previously believed. In Canada, there have been no large HEV seroprevalence studies and, generally, only symptomatic travelers returning from HEV-endemic countries are tested. 18 Although there are some data on US blood donors, 19, 20 HEV prevalence data in the Canadian blood donor population are lacking. We report on results of our study of HEV prevalence among Canadian blood donors, assessed by polymerase chain reaction (PCR), with a subset also tested for anti-HEV.
MATERIALS AND METHODS

Prevalence study
This study was carried out between July 2013 and December 2015 at Canadian Blood Services (CBS) and H emaQu ebec (H-Q). Ethics approval was obtained from the research ethics boards of both organizations. As it was part of a study examining seroprevalence of antibodies to Babesia microti, 21 donors were selected during the summer and fall months of 2013 from regions where ticks are more commonly found and in close proximity to areas in the United States where babesiosis has been reported. All donors from randomly selected collection sites in Nova Scotia, New Brunswick, Quebec (the majority of donations collected from clinics in southern Quebec), and the southern parts of Ontario and Manitoba were invited to participate in the study and asked to sign a consent form.
Residual plasma from routine donor testing samples was aliquoted and frozen at 2208C. Overall, 72% of donations at CBS and 95% of H-Q donations from consenting participants had an adequate volume of sample for testing.
Testing
All donors were tested for presence of HEV RNA by PCR at the National Microbiology Laboratory in Winnipeg, Manitoba, using a PCR kit (RealStar HEV-PCR kit, Altona, Diagnostics, Hamburg, Germany) in pools of 48 or 100 and an in-house nested PCR in pools of 100. A subset of randomly selected donors was also tested for the presence of anti-HEV IgG antibody using the Wantai HEV IgG ELISA (Wantai, Biological Pharmacy Enterprise Co.).
Donor sample pooling, processing, and RNA extraction A total of 13,993 blood donors were tested in pools of 48 or 100 using 100 mL from each donation for each pool size and each PCR method. Sixty-four pools of 48 comprising 3072 donors were prepared and the rest of the blood donations were screened in pools of 100. The switch to 100-member pools was required for technical reasons. The sensitivity of the 100-member pools was verified using serial dilutions of the international HEV RNA standard. One-hundred percent of six replicates at a concentration of 250 IU/mL tested PCR positive. The pools of 48 were centrifuged with a swinging bucket rotor (SW60, Beckman Coulter) and the pools of 100 donations with an SW40 rotor in an ultracentrifuge (Optima-L90, Beckman Coulter) at 200,000 3 g for 1 hour. Each pool was spiked with 10 mL of serum containing 100 IU/mL of HBV DNA as a control for the ultracentrifugation and extraction process. The viral pellet was resuspended in 100 mL of phosphate-buffered saline and extracted using an automated system (NucliSense EasyMag, bioM erieux) according to the manufacturer's instructions. The isolated nucleic acid was re-suspended in 60 mL of elution buffer and kept frozen at 2808C until use.
Serologic testing
Serum samples were tested using the Wantai HEV IgG ELISA kit (Wantai Biologic Pharmacy Enterprise). The Wantai assay uses a recombinant peptide corresponding to amino acid residues 396 to 606 of the major structural protein specified by ORF2 derived from a Chinese isolate of HEV. 22 Samples were tested on a semiautomated enzyme immunoassay processor (Crocodile miniWorkstation, Titertek-Berthold Berthold Detection Systems GmbH) and signal-to-cutoff (S/CO) ratios interpreted according to the manufacturer's instructions. All samples positive for anti-HEV IgG were further tested for anti-HEV IgM using Wantai HEV IgM ELISA kit by the same manufacturer.
HEV RNA amplification
To minimize potential for false-negative results, two different assays performed by two technologists were used: a commercial real-time reverse transcription (RT)-PCR amplification using a HEV RT-PCR kit assay (RealStar, Altona Diagnostic Technologies) was performed according to the manufacturer's instructions on a real-time PCR system (7500, ThermoFisher Scientific). In addition a heminested RT-PCR that detects largely divergent HEV variants was performed as previously described. 23 The analytical sensitivity of the commercial assay based on twofold dilution series of plasma samples inoculated with the first WHO international standard for HEV RNA was 15 IU/mL and that of the heminested RT-PCR was 10 IU/mL. Simulation of master pools of 100 donations was performed by combining 100 mL of twofold dilution series of the first WHO HEV nucleic acid test (NAT) standard and 9.9 mL of normal human serum and subjecting it to ultracentrifugation for 1 hour at 200,000 3 g, followed by extraction of the pellet using an automated system (NucliSense EasyMag, bioM erieux) according to the manufacturer's instructions. The detection limit after pooling and ultracentrifugation was 25 IU/pool or 2.5 IU/mL corresponding to 250 IU/mL of any single HEV RNA-positive donation in a pool of 100 HEV RNA-negative donations. The next twofold dilution of 125 IU/mL was detected among 70% of the replicates; therefore, our procedure would not reliably detect individual donations containing less than 250 IU/mL.
Validation of the pool processing
To validate the different steps of the processing of the donor pools (ultracentrifugation, extraction, and PCR amplification) a quantitative in-house real-time PCR for a known viral load of HBV DNA was used. The average Ct values of eight replicates spiked with 100 IU/mL HBV DNA was used to monitor the processing of each pool; a difference of Ct value of 3.4 or less from the expected average, corresponding to approximately 1 log variance, validated pool processing; processing of a specific pool was repeated if the Ct difference was more than 3.4.
Case-control study
All HEV antibody-positive donors (the cases) were invited by letter to participate in a scripted telephone interview about risk factors. For each case who participated, two control donors matched for age and sex were also invited to participate. Donors were asked about possible HEV risk factors, including residence outside of Canada and travel, exposure to animals, and consumption of pork products. Quebec donors were also asked about history of blood transfusion and exposure to well water.
Statistical analysis
Frequencies and percentages of HEV antibody-positive donors were calculated and compared by demographic variables using the chi-square test. Ninety-five percent CIs were calculated using the exact binomial method. Trend was assessed using the Armitage trend test. For the casecontrols study frequencies and percentages of donor responses to the interview questionnaire were calculated and compared using the chi-square test. For frequencies less than five the exact test was used. A logistic regression model was constructed with all variables that were significant in univariate comparison included as well as age and sex. Significance was defined as a p value of less than 0.05.
RESULTS
Testing
During the study period, 173,728 donors donated from both CBS and H-Q regions selected for the study; 26,260 (15.1%) of these donors donated at clinics selected for the study, and 13,993 (53%) were tested. Overall 21.4% of donors were from rural areas. At CBS sites, 72% of eligible donors consented to participate and had sufficient sample for testing. At H-Q sites, samples were available from 95% of the 43% of donors who consented to participate. In most cases, consent forms were not signed because of staffing issues in clinic, rather than donor refusal.
All 13,993 donations were tested for HEV RNA by PCR. There were no PCR-positive samples (95% CI, 0%-0.026%). A subset of 4102 donors was tested for anti-HEV IgG antibody. A total of 241 tested anti-HEV IgG antibody reactive for an overall seroprevalence of 5.9% (95% CI, 5.16%-6.59%; Table 1 ). IgM testing of all IgG-positive donors gave four IgM-positive results but the S/CO values were low compared to that seen in clinical cases and may represent tailing IgM from an infection in the past 6 months or a false-positive result. Male sex (p 5 0.04) and increasing age (p < 0.0001) were associated with anti-HEV IgG antibody reactivity (Table 2 ).
Case-control study
A total of 173 (72%) anti-HEV IgG antibody-positive donors and 261 (75%) age-and sex-matched controls (anti-HEV IgG antibody-negative donors) participated in the case-control interviews. Cases and controls were not significantly different by sex (p 5 0.11) or age group 
DISCUSSION
Hepatitis E prevalence in Canada is unknown, except for data available from diagnostic testing performed at the National Microbiology Laboratory. The majority of laboratory-confirmed HEV infections in Canada are travel related and belong to Genotype 1. During the past 4 years (2012-2015), there were, on average, 10 autochthonous HEV cases documented, all of which were caused by Genotype 3 except for one Genotype 4 (A. Andonov, personal communication, 2016). Asymptomatic individuals or symptomatic patients with no travel history are still unlikely to be tested for hepatitis E in Canada. This study is the first large HEV prevalence study to be reported in Canada. It does not encompass blood donors from across the country-for epidemiologic considerations related to the concurrent Babesia study, only collection sites in regions east of Saskatchewan were selected. However, donors from these areas do represent an otherwise reasonable cross-section of our Canadian blood donor population by age, sex, and by urban versus rural location. The overall anti-HEV IgG antibody prevalence in tested donors was 5.8%. It was associated with increasing age likely due to cumulative lifetime exposure and male sex, also noted in other developed countries. 13, 19, 20 The prevalence in Canadian donors was markedly lower than that found in a 2013 US study 19 (18.8%) also using the Wantai assay, and slightly lower than that found in a more recent US blood donor study 20 (7.7%) using a different antibody assay (MP Biomedical anti-HEV assay).
A limitation of the study, due to cost, was the use of pools rather than individual-donation PCR testing. Although no PCR-positive donors were identified, there may have been some donors with a viral load below the limit of detection of 250 IU/mL, The significance of very low HEV viral load in terms of transfusion risk to recipients is not well characterized although a study in England 11 indicated that transfusion transmission is not associated with viral loads of less than 2.6 log IU/mL. A recent study in Denmark found that transfusion of higher viral loads (920 IU/mL) may not lead even to anti-HEV IgG or IgM seroconversion in recipients. 24 Our case-control analysis identified living outside Canada as a significant predictor of HEV seropositivity, although since about 80% of HEV antibody-positive donors said they had never lived outside Canada it can explain only a minority of cases. However, most donors had travel history of some sort; thus, overseas exposure cannot be ruled out. Contact with farm animals was an independent risk factor, a potential endemic risk since HEV has been reported to be prevalent in Canadian domestic pigs. 25 An important limitation of our casecontrol study is that cases were defined by HEV serologic positivity and thus could have been infected at any time in the past. This, and a relatively small sample size, make assessment of the impact of common behaviors such as eating pork products difficult to assess. Studies of incident cases would be better able to determine the impact of diet, but may be difficult given the apparent low incidence of HEV. Although to date, not a single case of transfusionassociated HEV infection has been reported in Canada, it is unclear if this is due to very low incidence or to lack of recognition of this virus as a possible cause of transfusiontransmitted infection in this country. Although our sample size was large, and we identified no evidence of current infection, the upper 95% confidence limit shows HEV NAT reactivity of less than 1 in 3800 donations. Thus a much larger study will be required to more accurately quantify the risk. Some countries, such as the United Kingdom (SaBTO, March 22, 2016) , the Netherlands, 15 and France, have implemented some form of HEV donor testing, but most countries have not implemented any specific HEV mitigation measures. 26 An Alliance of Blood Operators Risk-Based DecisionMaking framework 27 is an appropriate tool for evaluating and analyzing alternative responses to this emerging blood safety concern, incorporating a range of factors, including the impact of infection on recipients, availability of effective treatment, and cost-effectiveness of various potential mitigation strategies. The latter consideration is particularly relevant since the attributable risk of transfusion-acquired HEV infection in developed countries, even among higher risk, immunocompromised transfusion recipients, is likely considerably less than the risk suggested by evidence indicating dietary exposure through pork-derived foodstuffs as the most likely source of indigenous HEV infection. 6 Universal or selective donor screening are possible options; however, there is currently no Health Canadaapproved HEV assay available for blood donor testing. Pathogen inactivation is unfortunately not totally effective against unenveloped viruses and would not be an option to reliably prevent HEV transfusion transmission. Underdiagnosis, due in part to lack of awareness, poorly characterized epidemiology of HEV infection in developed countries, and frequent nonspecific or asymptomatic infection, renders donor deferral as an ineffectual approach in the prevention of HEV transmission to blood recipients. However, improved transfusion adverse event surveillance and increasing physician awareness of HEV as a potential transfusion-transmitted infection may be useful. Efforts to better understand the risk of transfusion-associated HEV in Canada and optimal mitigation strategies continue and will be further informed by data from a large upcoming blood donor HEV prevalence study. In addition to the prevalence studies, both blood operators are actively involved in education of the transfusion medicine community, as well as public health colleagues, regarding HEV and the current risk of transfusion transmission in Canada. Based on the current data, the implementation of HEV donor testing is not being considered by Canadian blood operators at this time.
